Zealand rises as survodutide shows over 16% weight loss

Zealand Pharma A/S

28/04/2026 11:47

** Shares in Zealand Pharma ZELA.CO rise as much as 7.1% after Boehringer Ingelheim says experimental obesity drug survodutide led to average weight loss of up to 16.6% in a late-stage trial

** Jefferies says the result is "just enough for investors", but cautions that attention is now on whether the drug can show better gastrointestinal tolerability than Novo Nordisk's NOVOb.CO Wegovy

** More data is due when full results from the Phase III study are presented at an American Diabetes Association conference in June

** Boehringer has rights to solely develop and commercialise survodutide, with Zealand entitled to royalty payments on sales

** Zealand is the top gainer in Copenhagen .OMXC20; stock down ~30% YTD

(Reporting by Danilo Masoni)

((Danilo.Masoni@TR.com))